DiaCarta is a leading translational genomics and personalized diagnostics company based in Richmond, California with significant business operations in China. DiaCarta provides highly sensitive and advanced technologies that will change the landscape of precision medicine and molecular diagnostics by impacting healthcare treatment plans and the well-being of individuals around the world.
DiaCarta, a translational genomics and precision molecular diagnostics company, was established in 2011 to provide highly sensitive and advanced technologies that will improve the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world. With over 80 global patents, DiaCarta offers a range of products and services, from single-gene cancer mutation detection qPCR assays, colorectal cancer mutation detection panels, radiation therapy toxicity monitoring cfDNA test to its targeted NGS panels.
With over 14,600 square feet dedicated to a GMP-compliant lab space as well as CLIA and ISO 13485 certifications, a clinical laboratory facility in Nanjing, and offices in Shanghai, China. DiaCarta is well-equipped to serve clinical laboratories around the world. DiaCarta’s Clinical Service Lab at Nanjing, China is the world’s largest sequencing center housing several sophisticated sequencing instruments. The company is currently involved in the “One-Million Genome Project”, with plans to conduct Whole Genome Sequencing (WGS) on one million Chinese individuals.